Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ
Closed
Oct 14, 2026
Day's Range
39.9752 wk Range
39.97Overview - SUPN - Supernus Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
2.00B
P/E (Trailing)
40.66
P/E (Forward)
9.00
PEG Ratio
-0.11
Price / Sales (TTM)
2.81
Price / Book
2.26
EV / EBITDA
18.14
Profitability
Gross Margin
84.63%
Profit Margin
-13.23%
Operating Margin
-2.48%
Return on Assets
0.38%
Return on Equity
-10.48%
Ownership
Shares Outstanding
58.16M
Float
51.74M
Short % of Shares Outstanding
10.51%
Held by Insiders
4.32%
Held by Institutions
106.11%
Price stats
Beta
0.55
50-Day Avg
44.22
200-Day Avg
47.93
Dividends
Payout Ratio
0.00%
Analyst Consensus
4 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SUPN - Supernus Pharmaceuticals, Inc.
Peers - SUPN - Supernus Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- SUPNNASDAQSupernus Pharmaceuticals, Inc.2.33BMarket Cap-23.84%52-week change40.66P/E (Trailing)-13.23%Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.13.92BMarket Cap-4.14%52-week change19.90P/E (Trailing)20.91%Profit Margin
- ALKSNASDAQAlkermes plc7.45BMarket Cap+33.13%52-week change114.82P/E (Trailing)3.96%Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.6.74BMarket Cap+47.11%52-week change39.14P/E (Trailing)5.04%Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+42.25%52-week change24.14P/E (Trailing)17.69%Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals Ltd6.21BMarket Cap+49.26%52-week change81.61P/E (Trailing)9.59%Profit Margin
- RGCNASDAQRegencell Bioscience Holdings Limited5.18BMarket Cap-50.72%52-week change-1433.33P/E (Trailing)0.00%Profit Margin
Profile Summary - SUPN - Supernus Pharmaceuticals, Inc.
About
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
